 |
Trial Information
Summary: A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's LymphomaStatus: Recruiting Protocol Number: ML18223 Sponsor: Roche Austria GmbH Company Division: Pharmaceutical Official Scientific Title: A randomized, open-label study of MabThera as maintenance therapy compared with treatment-free observation on event-free survival in patients with aggressive B-cell non-Hodgkin's lymphoma Brief Summary: This study will evaluate the efficacy and safety of maintenance therapy with MabThera compared with observation (ie no treatment) in patients with aggressive B-cell non-Hodgkin`s lymphoma who had a complete response following first-line treatment with MabThera plus a chemotherapy regimen. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals. Target sample size is 440. Study Phase: IV Study Design / Study Details:
Study Type: Interventional
Condition: Non-Hodgkin's Lymphoma Intervention Type: Drug Intervention Name: rituximab[MabThera/Rituxan] Primary Outcome: 1. Clinical efficacy as measured by event-free survival Key Secondary Outcomes: 1. Quality of life, evolution of immunocompetence, safety, and overall survival Inclusion Criteria:
Exclusion Criteria:
Gender: Males or Females Age Limits: Min: 18 Years Accepts Healthy Volunteers: No Anticipated Start Date: May, 2004 Trial Registration Date: 08/29/2005 Date Last Updated: 06/17/2008
This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials. Trial listings updated: June 30, 2008 at 4:59:40 PM |
|
|
Patient Resources: [ Trial Listing
] [ Notification Services ] [ Drug
Directories ]
Copyright © 1995 - 2008, CenterWatch |
